LAVAL, QC, Sept. 27, 2018 /CNW Telbec/ - Servier Canada is pleased to announce that LANCORATM is now covered by the Régie de l'assurance maladie du Québec (RAMQ) for patients suffering from heart failure.
LANCORATM can be prescribed and reimbursed:
- For the treatment of people with heart failure in New York Heart Association (NYHA) class II or III, with left ventricular systolic dysfunction (ejection fraction ≤35%), in sinus rhythm with a resting heart rate of 77 beats per minute or greater:
- who have been hospitalised for worsening heart failure in the last 12 months; and
- who have been receiving for at least 4 weeks an Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB), in combination with a Beta-Blocker (BB) and a Mineralocorticoid Receptor Antagonist (MRA), unless contra-indicated or intolerant.
Heart failure rates continue to rise in Canada and it is a major cause disability, long and frequent hospital stays and premature death. Heart failure is a major burden for patients, their caregivers and the health care system with an estimated cost of over 2.8$ Billion per year in Canada. Heart failure is a complex and incurable condition, resulting in the heart not being able to pump sufficient blood to meet the body's demands. i
"With the burden of heart failure on the community and on the lives of heart failure patients, having access to innovative first-in class therapies such as LANCORATM for all eligible patients is a major step forward" said Dr Serge Lepage, past president for the Société Québécoise de l'Insuffisance Cardiaque, professor and director of the HF clinic at the University of Sherbrooke.
"Servier is committed to therapeutic progress to serve patients' needs and all of our activities are centered on achieving this objective. We are very pleased of the RAMQ's decision which will ensure that more eligible heart failure patients have access to the benefits of LANCORATM" said Frédéric Fasano, Chief Executive Officer of Servier Canada. "Servier continues to work actively with the other provinces to ensure that heart failure patients across Canada will soon have equal access to LANCORATM."
LANCORATM (ivabradine) is indicated for the treatment of stable chronic heart failure with reduced left ventricular ejection fraction (≤ 35%) in adult patients with NYHA Classes II or III who are in sinus rhythm with a resting heart rate ≥ 77 beats per minute, to reduce the incidence of cardiovascular mortality and hospitalisations for worsening heart failure.ii
About Servier Canada
Servier Canada Inc. is an affiliate of the independent French Servier Group. Our mission is to provide the Canadian medical community and its patients with innovative therapeutic solutions. As such, Servier Canada collaborates with various players in the healthcare system including researchers, entrepreneurs and innovators. In addition to these research partners, the Canadian International Center for Therapeutic Research (ICTR) is dedicated to clinical development with more than 50 studies conducted throughout Canada over the last 10 years. More information is available at www.servier.ca
i The Burden of Heart Failure: 2016 report on the health of Canadians. https://www.heartandstroke.ca accessed July 18th, 2018
ii LANCORA Product Monograph, May 2018
SOURCE Servier Canada Inc.
For further information: Media contact: Nadine DOUCET, Servier Canada, (450) 978-9700 ext. 4225, (514) 601-4881, [email protected], Website: www.servier.ca